

1 **Cervical Cancer Screening Outcomes for HIV-positive Women in the Lubombo**
2 **and Manzini regions of Eswatini – Prevalence and Predictors of a Positive**
3 **Visual Inspection with Acetic Acid (VIA) Screen**

4
5 *Short title:* Cervical Cancer Screening Outcomes for HIV-positive women in Eswatini

6
7 Rufaro Mapaona¹, Victor Williams^{1, 2}, Normusa Musarapasi¹, Sharon Kibwana³, Thokozani
8 Maseko¹, Rhinos Chekenyere¹, Sidumo Gumbo¹, Phetsile Mdluli¹, Hugben Byarugaba ¹,
9 Dileepa Galagedera¹, Arnold Mafukidze¹, Alejandra de Mendoza⁴, Prajakta Adsul⁵, Pido
10 Bongomin ¹, Christopher Loffredo⁴, Xolisile Dlamini ⁶, Deus Bazira³, Sylvia Ojoo ³, Samson
11 Haumba^{1, 3}

12
13
14
15

16 **Author Affiliations:**

- 17 1. Center for Global Health Practice and Impact, Georgetown University, Mbabane, Eswatini.
18 2. Julius Global Health, Julius Center for Health Sciences and Primary Care, University
19 Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
20 3. Center for Global Health Practice and Impact, Georgetown University Medical Center,
21 Washington DC, USA
22 4. Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA
23 5. University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, USA
24 6. Ministry of Health, Mbabane, Eswatini

25
26
27
28
29
30

31 **Corresponding Author**
32 Name: Victor Williams
33 Email: vmw20@georgetown.edu

34
35
36
37
38
39
40
41
42
43

44 **Abstract**

45 This study aimed to describe the prevalence and predictors of a positive VIA (visual inspection
46 with acetic acid) cervical cancer screening test in women living with human immunodeficiency
47 virus (HIV). We retrospectively analysed data from women aged ≥ 15 who accessed VIA
48 screening from health facilities in the Lubombo and Manzini regions of Eswatini.
49 Sociodemographic and clinical data from October 2020 to June 2023 were extracted from the
50 client management information system. VIA screening outcome was categorised into
51 negative, positive, or suspicious. A logistic regression model estimated the adjusted odds ratio
52 (AOR) of the predictors of a positive VIA screen at $p < 0.05$ with 95% confidence intervals. Of
53 23,657 participants, 60.8% ($n=14,397$) were from the Manzini region. The mean age was 33.3
54 years (standard deviation 7.0), and 33% ($n=7,714$) were first-time screens. The prevalence of
55 a positive VIA was 2.6% (95% CI: 2.2%, 3.0%): 2.8% (95% CI: 2.2%, 3.5%) in Lubombo and 2.4%
56 (95% CI: 2.0%, 2.9%) in Manzini ($p=0.096$). Screening at mission-owned (OR 1.40; $p=0.001$),
57 NGO-owned (OR 3.08; $p < 0.001$) and industrial/workplace-owned health facilities (OR 2.37;
58 $p=0.044$) were associated with positive test results compared to government-owned health
59 facilities, and being within the 35–44 age group (OR 1.26; $p=0.017$) compared to 25–34 years
60 age group was a positive predictor of a positive VIA screen. Negative predictors of positive
61 VIA test were: being on anti-retroviral therapy (ART) for 5–9 years (OR 0.76; $p=0.004$) and ≥ 10
62 years (OR 0.66; $p=0.002$) compared to < 5 years; and having an undetectable viral load (OR
63 0.39; $p < 0.001$) compared to unsuppressed. Longer duration on ART and an undetectable viral
64 load reduced the odds, while middle-aged women and screening at non-public health facilities
65 increased the odds of a positive VIA screen.

66
67
68

69 Introduction

70 Cervical cancer continues to be a leading cause of morbidity and mortality for women, despite
71 being preventable by vaccination against the human papillomavirus (HPV) and curable if
72 detected and treated early. There were an estimated 604,000 new cervical cancer cases and
73 342,000 deaths worldwide in 2020, and it is the fourth most frequently diagnosed cancer in
74 women [1].

75

76 There are substantial inequalities in the global cervical cancer burden: incidence is three times
77 higher in countries with lower levels of human development, and more than 90% of deaths
78 occur in these countries. The highest regional incidence and mortality occurs in Sub-Saharan
79 Africa, where age-standardised incidence rates in Eastern Africa (40.1), Southern Africa (36.4)
80 and Middle Africa (31.6) [2] are far higher than the threshold of 4 per 100,000 established by
81 the World Health Assembly's Global Strategy for cervical cancer elimination [1].

82

83 Most cervical cancer cases (99.7%) are caused by persistent HPV infection [3], which is more
84 prevalent in HIV-infected women [4]. The natural history of HPV infection has a slow, 10-15-
85 year progression to pre-cancer in immuno-competent people. In HIV-infected women, the
86 condition progresses more frequently and quickly [5]. Cervical cancer is classified as an AIDS-
87 defining illness. It is associated with lower CD4 cell counts and a lack of anti-retroviral therapy
88 (ART) among women living with HIV [6]. Globally, approximately 1 in 20 cervical cancers is
89 attributable to HIV. In sub-Saharan Africa, about 1 in 5 cervical cancers is due to HIV, which
90 threatens the gains that improving access to HIV care and treatment has made in prolonging
91 the life expectancy of these women. However, it is essential to note that although cervical

92 pre-cancer among women living with HIV is common, those who receive regular cervical
93 screenings among this population have low incidence rates of invasive cervical cancer [7].

94

95 Disparities in cervical cancer incidence and mortality reflect unequal access to and coverage
96 of comprehensive prevention (including HPV vaccination), screening and treatment of pre-
97 cancerous lesions, and diagnosis and treatment of invasive cancers. The availability of these
98 services is suboptimal in low- and middle-income countries. As of 2020, less than 30% of
99 lower-middle-income countries had introduced the HPV vaccine, compared to 85% in high-
100 income countries. Still, in 2020, less than 35% of low-income countries had national cervical
101 cancer screening programs, and less than 30% reported the availability of pathology services,
102 cancer surgery, and other cancer management services [8].

103

104 Secondary prevention reduces cervical cancer incidence and mortality by identifying and
105 treating women with pre-cancerous lesions. The World Health Organisation (WHO)
106 recommends HPV DNA testing as the primary screening test for cervical cancer, but this
107 technology is not yet available or accessible in many countries. Cytology-based (or pap smear)
108 screening has been successful when implemented as part of national programmes with high
109 coverage and in settings where resources exist for patient follow-up, additional diagnostic
110 tests (colposcopy and pathology), and disease management [9]. In low-resource settings, the
111 "see-and-treat" approach, which includes naked eye or digitally enhanced visual inspection
112 with acetic acid (VIA) to detect pre-cancerous lesions and the use of cryotherapy (liquid
113 nitrous oxide ablation) to freeze and destroy pre-cancerous tissue, has been successfully
114 implemented. However, the quality of VIA depends heavily on provider competence and the
115 test's sensitivity, which is variable [10–12].

116

117 [Cervical Cancer in Eswatini](#)

118 Eswatini faces a high dual burden of HIV and cervical cancer. The country's HIV prevalence of
119 25.9% among adults is one of the highest in the world [13], and Eswatini has the highest age-
120 standardised cervical cancer incidence rate of 84.5 per 100,000. Only 17.6% of the country's
121 estimated 336,037 women aged 15 – 64 years have been screened at least once for cervical
122 cancer [14] ⁽¹⁶⁾. Coverage is only slightly better for women living with HIV: estimates suggest
123 that only 20.3% of this population has been screened [15].

124

125 Given the high dual burden of HIV and cervical cancer in the country, the Eswatini Ministry of
126 Health has developed several policies. In particular, the National Cancer Prevention and
127 Control Strategy of 2019 has set clear targets to increase the percentage of health facilities
128 providing screening, early detection, and linkage to treatment for all cancers to 60% by 2022.
129 However, only 43% of health facilities have achieved this goal. Current guidelines recommend
130 screening as soon as one is sexually active for HIV-positive women, while HIV-negative women
131 or those with unknown status can start screening from ≥ 25 years. The recommended
132 frequency of cervical cancer screening is also based on HIV status and HPV infection status of
133 patients (if known). Women living with HIV are screened annually, while it is every two years
134 for HIV-negative women and extended to three years for those who are HIV and HPV-
135 negative. All screening services are free in public hospitals. HPV DNA testing is not yet
136 available in the country. Fidelity to these guidelines is not monitored routinely, and when
137 done, records for non-HIV women may not be up to date. In this study, we describe the
138 cervical cancer screening outcomes, prevalence and predictors of a positive cervical screen
139 among HIV-positive women accessing services at selected health facilities in two regions of
140 Eswatini.

141 Methods

142 Study design and setting

143 This was a retrospective cohort study among HIV-positive women receiving HIV care at select
144 health facilities in the Lubombo and Manzini regions of Eswatini under the United States
145 Government funded Support Eswatini Achieve Sustained HIV Epidemic Control (SEASEC)
146 project. The SEASEC project is a comprehensive HIV care and treatment program
147 implemented by the Eswatini Ministry of Health (MOH) and supported by Georgetown
148 University. SEASEC supports the provision of cervical cancer screening and treatment of pre-
149 cancerous lesions for all women living with HIV. As part of the program, healthcare workers
150 have been trained to offer VIA, cryotherapy, and Loop Electrosurgical Excision Procedure
151 (LEEP) services. Screening supplies and equipment have also been procured and installed at
152 all seventy-five health facilities providing cervical cancer screening services in Lubombo and
153 Manzini. Additional interventions include support for quality improvement and collection and
154 use of service delivery data.

155 Health facilities in the Lubombo and Manzini regions are described in Table 1. Lubombo region
156 has fifty-four health care facilities, including two hospitals (with in-patient services), one rural
157 health centre, one public health unit (equivalent to a multi-department health centre), and
158 forty-two primary health clinics. Manzini region has one hundred and twenty-three health
159 facilities, including four hospitals (with in-patient services), two public health units (equivalent
160 to health centres), and one hundred and seventeen primary health clinics. The SEASEC
161 Program supports eighty-six public, private or faith-based health facilities across both regions
162 (Table 1).

163
164
165
166

167 Table 1: Health facilities in Manzini and Lubombo regions (*Obtained from Manzini and Lubombo*
 168 *Regional Health Management Team Quarterly Report, Q2 2023*)

Health Facility Type	Manzini Region			Lubombo Region			Description of health facilities
	Total Health Facilities	SEASEC Supported		Total Health Facilities	SEASEC Supported		
		Total	Cervical services		Total	Cervical services	
Government	41	26	26	30	25	22	-No fees for all services -Receives PEPFAR* support for HIV/TB services -Receives HIV/TB supplies from MOH
Faith-based	19	13	7	9	9	9	-Owned by a faith-based entity -Low user fees -Free HIV/TB services -Receives government support -Receives PEPFAR support for HIV/TB services -Receives HIV/TB supplies from MOH
NGO	11	5	5	2	2	1	-Owned by an NGO -No user fees -Mainly HIV/TB services -Receives PEPFAR support for HIV/TB services -Receives HIV/TB supplies from MOH
Industrial/Work place	0	0	0	7	7	5	-Owned by the company -No user fees for employees -Non-employees pay user fees -Receives PEPFAR support for HIV/TB services -Receives HIV/TB supplies from MOH
Private	52	0	0	6	0	0	-Owned by private entities -Services vary (general medical to specialised) -Fees for all services
Total	123	44	38	54	42	37	

169 *United States Presidents Emergency Plan for AIDS Relief

170

171 The locations of these 75 health facilities that implement the SEASEC Program-supported
 172 cervical screening activities are shown in Figure 1.

173

174

175

176 *Figure 1: Distribution of health facilities providing cervical cancer services in the Lubombo and*
 177 *Manzini region supported by the SEASEC Program (Generated using SEASEC Program data)*

178

179 [Study participants, sample size and sampling](#)

180 We generated data for the study from patient attendance records from October 2020 to June

181 2023. The data are collected using standardised service registers provided by the Eswatini

182 Ministry of Health (MOH) to all public health facilities. Our study participants were HIV-

183 positive women screened for cervical cancer from October 2020 to June 2023 at any of the

184 75 health facilities described above. Data from the two regions indicate that, as of June 2023,
185 a total of 69,529 women aged 15 years or older were living with HIV, and approximately
186 19,616 of these had received at least one cervical cancer screening [15]. Based on these data,
187 a minimum of 95% of women living with HIV who have received a cervical screen (18,635) will
188 be included in this analysis.

189

190 [Data sources and study variables](#)

191 Data were extracted from the National Electronic Medical Record: Client Management
192 Information System (CMIS) on the 2nd of August 2023. The required variables were filtered
193 and extracted per the study objectives. The variables describe the patient's sociodemographic
194 and clinical information (Table 2). Age was grouped into eight categories using 5-year age
195 bands from 15 to 50 years, while parity was categorised into 0, 1, 2 – 3, 4 – 5, and ≥ 6 . Marital
196 status was grouped into two classes: married/living with a partner or single. The patient's last
197 viral load was categorised into three groups – undetectable (< 50), suppressed ($50 < 1000$), and
198 unsuppressed (≥ 1000). The timing of the cervical screening was divided into three groups –
199 first-time screening, post-treatment follow-up screening, and rescreening per the national
200 guideline. The VIA screening outcome was categorised into negative, positive, and suspicious.
201 The outcome variable for this study is the prevalence of a positive VIA screen, defined as the
202 proportion of women with a positive VIA screen.

203

204 [Statistical analysis](#)

205 Data was extracted in .xls format and imported into Stata 17 (College Station, TX) for cleaning
206 and analysis. Descriptive analysis summarised underlying trends and seasonal patterns. Key
207 patient characteristics are presented in Table 2, disaggregated by the cervical screening
208 outcome. Casewise analysis was used since all the patients had the outcome of interest. The

209 prevalence of positive VIA screens was presented overall and disaggregated by other patients'
210 sociodemographic and clinical information.

211 A new binary dependent variable – presence or absence of cervical lesion - was generated to
212 determine the predictors of a positive cervical screen. A logistic regression model was fitted
213 using the dependent variable and the different sociodemographic and clinical variables as
214 predictors. A univariate model was initially built using each of the independent variables, and
215 a stepwise forward and backward elimination process was used to select variables for
216 inclusion in the final multivariate model at $p=0.20$. The final predictors were determined from
217 the multivariate model at $p<0.05$.

218 [Ethical review and approval](#)

219 This study is covered under the protocol approved by the Eswatini Health and Human
220 Research Review Board (EHHRRB 116/2022) for Georgetown University to analyse program
221 data for dissemination. Additional approval has been obtained from the Georgetown
222 University Institutional Review Board (GU - IRB) (STUDY 00006034) and the United States
223 Centers for Disease Control (CDC) (Accession #: CGH-ESW-9/14/23-15af6). Anonymised data
224 were used to ensure confidentiality and the EHHRRB also approved an application for a waiver
225 of written informed consent from participants since the data is from routine care extracted
226 from the electronic medical records.

227 [Results](#)

228 [Sociodemographic and screening outcome characteristics of study participants](#)

229 Table 2 presents the descriptive characteristics of all HIV-positive patients included in the
230 study and disaggregated by screening outcomes (negative, positive, and suspicious cervical
231 screens). Overall, 23,657 patients accessed cervical screening services. Six hundred and three
232 (2.6%) had a positive screen, and 60.8% ($n=14,397$) were from the Manzini region. The mean
233 age was 33.3 years (SD 7.0). Analysis by 5-year categories showed that screening increased

234 gradually from 1.2% (n= 295) in the 15 – 19 age group to 25% (n=5949) in the 30 – 34 age
 235 group and was consistent for both positive and negative participants. Most patients (67.3%,
 236 n=15,798) were rescreened, while 32.6% (n=7,714) were screened for the first time. About
 237 69% (n=10, 451) were single, and more than half of the patients (55.9%, n=9,373) had a parity
 238 of 0. This was similar across the three outcome groups. The majority (96.4%, n=22,770) of the
 239 patients were on a dolutegravir-based ART regimen; the median duration of ART was 6.0 years
 240 (IQR 4.0, 9.0), and 95% overall had a suppressed and undetectable viral load. This is similar
 241 for those who screened positive (94%, n=566).

242

243 **Table 2: Descriptive characteristics of participants**

Patient Characteristics	Negative (N = 22957)	Positive (N = 603)	Suspicious (N = 97)	Total (N = 23657)
Region				
Lubombo	8976 (39.1%)	256 (42.5%)	39 (40.2%)	9297 (39.2%)
Manzini	13981 (60.9%)	347 (57.5%)	58 (59.8%)	14397 (60.8%)
Age (years)				
15-19	284 (1.2%)	11 (1.8%)	0 (0.0%)	295 (1.2%)
20-24	2123 (9.2%)	54 (9.0%)	2 (2.1%)	2194 (9.3%)
25-29	4972 (21.7%)	108 (17.9%)	14 (14.4%)	5098 (21.5%)
30-34	5776 (25.2%)	147 (24.4%)	24 (24.7%)	5949 (25.1%)
35-39	5268 (22.9%)	155 (25.7%)	24 (24.7%)	5448 (23.0%)
40-44	3138 (13.7%)	97 (16.1%)	18 (18.6%)	3268 (13.8%)
45-49	1215 (5.3%)	27 (4.5%)	14 (14.4%)	1256 (5.3%)
≥50	181 (0.8%)	4 (0.7%)	1 (1.0%)	186 (0.8%)
Mean (SD)	33.29 (7.06)	33.53 (7.06)	36.47 (6.78)	33.31 (7.06)
Parity				
0	9078 (55.9%)	238 (57.2%)	33 (51.6%)	9373 (55.9%)
1	2295 (14.1%)	61 (14.7%)	14 (21.9%)	2377 (14.2%)
2-3	3687 (22.7%)	89 (21.4%)	12 (18.8%)	3789 (22.6%)
4-5	1010 (6.2%)	22 (5.3%)	1 (1.6%)	1038 (6.2%)
≥6	179 (1.1%)	6 (1.4%)	4 (6.3%)	189 (1.1%)
Median (Q1, Q3)	0.0 (0.0, 2.0)	0.0 (0.0, 2.0)	0.0 (0.0, 2.0)	0.0 (0.0, 2.0)
Duration on ART (Years)				
Median (Q1, Q3)	6.0 (4.0, 8.0)	6.0 (3.0, 9.0)	7.0 (4.0, 8.0)	6.0 (4.0, 9.0)
Facility Type				
Government	12666 (55.2%)	260 (43.1%)	49 (50.5%)	13003 (54.9%)
Faith-based	6760 (29.4%)	180 (29.9%)	32 (33.0%)	6981 (29.5%)
NGO	3420 (14.9%)	157 (26.0%)	11 (11.3%)	3588 (15.1%)
Industrial/Workplace	111 (0.5%)	6 (1.0%)	5 (5.2%)	122 (0.5%)
Cervical Screening Type				
First Time Screening	7427 (32.4%)	244 (42.0%)	29 (30.9%)	7714 (32.6%)
No Outcome	10 (0.0%)	22 (3.8%)	2 (2.1%)	34 (0.1%)

Post Tx FU	70 (0.3%)	34 (5.9%)	1 (1.1%)	105 (0.4%)
Rescreening	15432 (67.3%)	281 (48.4%)	62 (66.0%)	15798 (66.8%)
Marital status				
Married/living with partner	4455 (30.5%)	131 (34.8%)	30 (56.6%)	4634 (30.7%)
Single	10164 (69.5%)	245 (65.2%)	23 (43.4%)	10451 (69.3%)
Last VL Outcome (cells/ml)				
No VL Result	657 (2.9%)	12 (2.0%)	2 (2.1%)	671 (2.8%)
Suppressed (50<1000)	2389 (10.4%)	97 (16.1%)	8 (8.2%)	2494 (10.5%)
Unsuppressed (≥1000)	406 (1.8%)	25 (4.1%)	3 (3.1%)	434 (1.8%)
Undetectable (<50)	19505 (85.0%)	469 (77.8%)	84 (86.6%)	20095 (84.8%)

244

245 Prevalence of positive VIA screen

246 The overall prevalence of a positive cervical screen was 2.6% (95% CI: 2.2%, 3.0%): 2.8% (95%
 247 CI: 2.2%, 3.5%) in Lubombo and 2.4% (95% CI: 2.0%, 2.9%) in Manzini (p=0.096). The
 248 prevalence was further analysed by age group, ART duration, parity, and cervical screening
 249 type (Table 3). The prevalence ranged from 2.1% (95% CI: 1.5%, 3.0%) in the 25 – 29 years age
 250 group to 3.7% (95% CI: 1.3%, 9.9%) in the 15 - 19 years age group, and it was statistically
 251 higher in the 40 - 44 years age group in Lubombo (4.2%; 95% CI: 2.5%, 6.8%) compared to
 252 those in Manzini (2.1%; 95% CI: 1.4%, 3.1%) (p=0.001). Patients with parity ≥6 had an overall
 253 higher prevalence of 3.2% (95% CI: 0.5%, 19.5%), while those with parity=0 had a higher
 254 prevalence in Lubombo compared to Manzini (p=0.004). Prevalence was higher in patients
 255 receiving post-treatment follow-up screening at 32.7% (95% CI: 20%, 49%) and lowest in
 256 rescreening patients.

257

258

259

260

261

262

263

264 **Table 3: Prevalence of a positive cervical screen**

Patient Characteristics	% Prevalence (95% Confidence Interval)			P-Value*
	Lubombo	Manzini	Overall	
Region	2.8% [2.2,3.5]	2.4% [2.0,2.9]	2.6% [2.2,3.0]	
Facility Type				
Government	2.1% [1.6,2.8]	1.9% [1.4,2.6]	2.0% [1.6,2.5]	0.440
Mission	4.7% [3.2,7.0]	1.6% [1.0,2.6]	2.6% [1.9,3.5]	<0.001
NGO	0.0%	4.4% [3.5,5.6]	4.4% [3.5,5.6]	-
Industrial/Workplace	5.1% [2.3,10.9]	0.0%	5.1% [2.3,10.9]	-
Age group (years)				
15-19	5.9% [1.4,21.7]	2.3% [0.7,7.4]	3.7% [1.3,9.9]	0.108
20-24	2.4% [1.1,5.2]	2.6% [1.5,4.4]	2.5% [1.6,3.9]	0.789
25-29	2.4% [1.3,4.2]	2.0% [1.2,3.2]	2.1% [1.5,3.0]	0.389
30-34	2.6% [1.5,4.4]	2.4% [1.6,3.6]	2.5% [1.8,3.4]	0.632
35-39	2.4% [1.4,4.1]	3.1% [2.3,4.3]	2.9% [2.2,3.8]	0.136
40-44	4.2% [2.5,6.8]	2.1% [1.4,3.1]	3.0% [2.1,4.2]	0.001
45-49	2.1% [1.0,4.7]	2.2% [1.3,3.6]	2.2% [1.4,3.4]	0.932
≥50	4.9% [1.8,12.3]	0.0%	2.2% [0.8,5.6]	-
ART duration				
<5 years	3.2% [2.2,4.8]	2.8% [2.2,3.7]	3% [2.4,3.7]	0.332
5-9years	2.5% [1.7,3.6]	2.3% [1.7,3.1]	2.4% [1.9,3.0]	0.425
≥10years	2.8% [1.8,4.4]	2.0% [1.4,2.8]	2.3% [1.7,3.2]	0.070
Parity				
0	3.2% [2.2,4.6]	2.2% [1.6,3.0]	2.6% [2.0,3.2]	0.004
1	3.1% [1.6,5.9]	2.2% [1.1,4.4]	2.6% [1.6,4.1]	0.184
2-3	2.7% [1.4,5.0]	2.1% [1.2,3.6]	2.4% [1.6,3.5]	0.272
4-5	2.0% [0.8,5.0]	2.3% [0.7,7.0]	2.1% [1.0,4.4]	0.768
≥6	4.7% [0.7,26.4]	0.0%	3.2% [0.5,19.5]	0.097
Frequency of screening				
First Time Screening	4.0% [2.4,6.5]	2.9% [2.2,3.9]	3.2% [2.5,4.1]	0.068
Post Treatment Follow-Up	37.1% [16.5,64]	30.4% [15.6,50.9]	32.7% [20,49.0]	0.491
Rescreening	1.9% [1.4,2.6]	1.7% [1.3,2.1]	1.8% [1.5,2.2]	0.235

265 *Compares Lubombo and Manzini

266

267 **Follow-up VIA screening**

268 Two hundred and twenty-three of 603 patients with a positive first VIA result had follow-up

269 VIA results. Of the 223, 125 (56%) had a negative result, 89 (40%) had a positive result, and 9

270 (4%) had a suspicious result. Only 21 of 97 patients with a suspicious result had a follow-up

271 VIA result: 5 (23.8%) were negative, 3 (14.3%) were positive, and 13 (61.9%) remained

272 suspicious. Of 22,957 patients with a negative VIA result, follow-up screening data was

273 available for 8403 patients: 8,288 (98.6%) remained negative, 50 (0.6%) were positive, and 13
274 (0.15%) had a suspicious result.

275 [Predictors of a positive cervical screen](#)

276 The predictors of a positive cervical screen are presented in Table 4. In the univariate analysis,
277 screenings at mission-owned, NGO-owned, and industrial/workplace-owned health facilities
278 were significant positive predictors of a positive cervical cancer screening result compared to
279 screening at a government-owned health facility. Being on ART for 5 – 9 years and ≥ 10 years
280 compared to being on ART for less than 5 years and having an undetectable viral load
281 compared to an unsuppressed viral load were significant negative predictors of a positive
282 cervical screen.

283 In the multivariate analysis, significant negative predictors of a positive cervical screen were
284 residing in the Manzini region (OR 0.55; 95% CI: 0.45, 0.67; $p < 0.001$) compared to Lubombo;
285 being on ART for 5 – 9 years duration (OR 0.76; 95% CI: 0.62, 0.92; $p = 0.004$) and ≥ 10 years
286 (OR 0.66; 95% CI: 0.50, 0.85; $p = 0.002$) compared to less than 5 years; and having an
287 undetectable viral load result (OR 0.39; 95% CI: 0.26, 0.59; $p < 0.001$) compared to an
288 unsuppressed viral load. Being screened at mission-owned (OR 1.40; 95% CI: 1.15, 1.72;
289 $p = 0.001$), NGO-owned (OR 3.08; 95% CI: 2.41, 3.95; $p < 0.001$) and industrial/workplace-
290 owned (OR 2.37; 95% CI: 1.02, 5.49; $p = 0.044$) compared to government-owned health
291 facilities, and being within the 35 – 44 age group (OR 1.26; 95% CI: 1.04, 1.53; $p = 0.017$)
292 compared to 25-34 years age group, were significant positive predictors of a positive cervical
293 screen.

294

295

296

297 **Table 4: Univariate and Multivariate Predictors of Abnormal Cervical Screen**

Predictor	Univariate		Multivariate	
	OR (95% CI)	P-Value*	OR (95% CI)	P-Value*
Region				
Lubombo	1		1	
Manzini	0.87 (0.74, 1.02)	0.096	0.55 (0.45, 0.67)	<0.001
Health Facility Type				
Government	1		1	
Mission	1.30 (1.07, 1.57)	0.008	1.40 (1.15, 1.72)	0.001
NGO	2.24 (1.83, 2.74)	<0.001	3.08 (2.41, 3.95)	<0.001
Industrial/Workplace	2.63 (1.15, 6.04)	0.022	2.37 (1.02, 5.49)	0.044
Age (years)				
25-34	1		1	
15-24	0.88 (0.67, 1.16)	0.358	1.04 (0.78, 1.39)	0.777
35-44	1.11 (0.84, 1.46)	0.459	1.26 (1.04, 1.53)	0.017
45+	0.82 (0.53, 1.27)	0.376	0.83 (0.55, 1.24)	0.361
Duration on ART (Years)				
<5 years	1		1	
5 – 9 years	0.79 (0.66, 0.94)	0.009	0.75 (0.62, 0.92)	0.004
=> 10 years	0.78 (0.62, 0.99)	0.038	0.66 (0.50, 0.85)	0.002
Marital status				
Married/Partner	1			
Single	0.82 (0.66, 1.02)	0.070		
Parity				
0	1			
1	1.01 (0.76, 1.35)	0.925		
2-3	0.92 (0.72, 1.18)	0.511		
4-5	0.83 (0.53, 1.29)	0.411		
≥6	1.28 (0.56, 2.91)	0.559		
Last Viral Load Outcome				
Unsuppressed (≥1000)	1		1	
Suppressed (50<1000)	0.66 (0.42, 1.04)	0.071	0.66 (0.42, 1.04)	0.071
Undetectable (<50)	0.39 (0.26, 0.59)	<0.001	0.39 (0.26, 0.59)	<0.001

298

299

300 Discussion

301 We aimed to describe the cervical cancer screening outcomes, prevalence, and predictors of
 302 a positive cervical screen in the women living with HIV who accessed services at select health
 303 facilities in the Lubombo and Manzini regions of Eswatini. Our study findings suggest that the
 304 percent positivity for cervical cancer screening tests among WLHIV is 2.6%, lower than
 305 reported in the literature from studies in similar settings, regardless of the type of screening

306 test used. A previous cross-sectional study in Eswatini found that the presence of cervical
307 lesions was higher in HIV-positive (22.9%) than HIV-negative women (5.7%; $p < 0.0001$) [16],
308 and another study in Eswatini found a VIA positivity rate of 9% in the general population [17].
309 Elsewhere in Africa, a large cohort study of women in Zambia who were screened with VIA
310 and digital cervicography (VIAC) had a positivity rate of 10.4% for the general population, with
311 WLHIV having a much higher rate of 53.3% [18]. In Nigeria, a study using program data found
312 a VIA positivity rate of 7.1% [19]. In another study assessing HPV testing for WLHIV, 46.5% in
313 Burkina Faso and 43.8% in South Africa had a positive HPV test [20]. In a hospital-based study
314 conducted in Ethiopia, the prevalence of a pre-cancerous cervical lesion was 9.3% among
315 WLHIV [21].

316 This finding of a lower-than-expected positivity rate in Eswatini compared to the studies cited
317 above points to the need for further research into the screening offered in health facilities.
318 Given the literature around VIA screening, the learning curve to implement this screening test
319 is high, and the results during initial phases often reflect lower positivity rates. Future
320 research can help determine whether the lower-than-expected positivity rate is due to a need
321 for strengthening screening services or is an accurate reflection of rates among this
322 population. Given the move towards the recent WHO guidelines in Eswatini, HPV-DNA is being
323 recommended for use as the primary screening test. Eswatini has yet to fully roll out this
324 testing modality; hence, ensuring the quality of the existing VIA screening test is essential
325 even as the government works to expand access to HPV DNA testing.

326 Another observation from our study is that the prevalence of a positive screening result was
327 associated with accessing services at faith-based, NGO-owned and industrial/workplace-
328 owned health facilities. This observation could be due to several reasons. First, personnel at

329 these types of health facilities who provide cervical screening services are assigned to VIA
330 screening as part of their ongoing, long-term responsibilities, which enables them to acquire
331 skills and expertise over time. In comparison, health personnel at government-owned health
332 facilities are not stationed at the VIA unit; they rotate from their role to another unit or health
333 facility every twelve months. This rotation limits the skill and expertise in cervical screening.
334 Secondly, the facilities with more positive screens have access to better screening equipment
335 with better utilisation than government-owned facilities. Third, these health facilities enforce
336 higher quality standards on VIA screening with strict adherence to the screening standard
337 operating procedure (SOP) and supervision than government-owned health facilities. Fourth,
338 they provide supplemental training for their staff in addition to the required minimum
339 training for health personnel providing VIA and cervical cancer services.

340 A positive screening result in our study was also associated with being aged between 35 – 44
341 years, compared to older and younger age groups. This finding is consistent with findings from
342 several sub-Saharan African countries that the burden of cervical cancer attributable to HIV
343 is highest among younger women aged less than 45 [22]. Longer duration on ART and an
344 undetectable viral load were protective in our analysis, which is consistent with other studies
345 and could be attributed to the increased immune function, which reduces the incidence and
346 progression of squamous intraepithelial lesion (SIL) and cervical intraepithelial neoplasia (CIN)
347 and, ultimately, the incidence of invasive cervical cancer when patients are stable on ART
348 [23]). Other predictors of positive screening results vary in the literature. Studies have found
349 that predictors of pre-cancerous cervical lesions or positive cervical cancer screening results
350 among WLHIV include increasing parity [24], a history of multiple sexual partners, and sexually

351 transmitted infections [25]. In the general population, predictors of VIA positivity include
352 having multiple sexual partners, having an early sexual debut, and being older [17,26].

353 Our study had several strengths, notably the large sample size of nearly 24,000 women.
354 Regionwide coverage of public, faith-based, NGO-owned and industrial/workplace-owned
355 health facilities limits any possible effects of clinic-based selection bias. There was a high rate
356 of data completion on the results of screening tests, with very few participants lost to follow-
357 up or with missing data. Given our study's large number of health facilities, the findings highly
358 represent the two regions. On the contrary, the study conclusions were limited in
359 generalizability, as the SEASEC project supported all sites included in this study. These findings
360 may not apply to settings not supported by the SEASEC project. This is also important for
361 planning future research to outline the role of the support partners, the characteristics of the
362 settings, and the support received. Another limitation of our study is excluding private health
363 facilities, which are not SEASEC-supported. A challenge with private health facilities includes
364 difficulty accessing their data, uncertainty about the type of services they offer, and whether
365 they adhere to standard MOH guidelines.

366 Eswatini has yet to achieve its target of scaling up cervical cancer services. Scaling up cervical
367 cancer services to more health facilities with targeted, demand-driven activities and patient
368 education will increase cervical screening coverage in Eswatini. More positive screens can be
369 identified, and women can be offered treatment with a higher coverage.

370 Government-owned health facilities should adopt practices to increase accountability for
371 cervical screening services with measures to track adherence to cervical screening standards,
372 standard operating procedures, supportive supervision, and mentoring for staff who require
373 additional skills.

374 Early HIV case finding and scaling up ART uptake for women in different at-risk populations
375 can limit non-suppression and lower the risk of a positive cervical screen. Moreover, scaling
376 up HIV services overall will increase cervical screening opportunities.

377 Although Eswatini has just commenced HPV vaccinations for eligible females, the
378 implementation has not been country-wide due to the limited availability of the vaccine. This
379 should be scaled up to all regions with provisions to make it accessible for eligible residents
380 of remote, hard-to-reach locations. The general public should receive adequate information
381 on the vaccine's benefits, including details of where and how they can access additional
382 information on the HPV vaccines.

383 Finally, additional studies are required to identify other possible causes of the lower-than-
384 expected VIA positivity rate in selected facilities with strategies to address the identified gaps.
385 Ongoing screening with VIA should be standardised across all health facilities, focusing on
386 improving the health system structures required for a comprehensive screening program.
387 Efforts to expand access to HPV DNA testing should be fast-tracked, prioritising screening for
388 vulnerable women, including WLHIV.

389

390

391

392

393

394

395

396

397 [Acknowledgements](#)

398 We thank all the clients and healthcare workers, without which this study would not have
399 been possible. We also thank the monitoring and evaluation team at Georgetown University
400 Eswatini, who diligently collected the data reported in the article.

401 [Funding](#)

402 The Support Eswatini Achieve and Sustain HIV Epidemic Control (SEASEC) Program is
403 supported by the U.S President's Emergency Plan for AIDS Relief through the Centers for
404 Disease Control and Prevention (Co-operative Agreement No.:NU2GGH002294),
405 implemented by Georgetown University in collaboration with the Government of the
406 Kingdom of Eswatini. The funders had no role in the conceptualization of the study, study
407 design, data collection and analysis, decision to publish and preparation of the manuscript.

409 [Contributions](#)

410 RM, VW, SO and SH conceptualised the study. NM, TM, RC, SG, PM, HB, and DG participated
411 in data capturing and verification at health facilities supervised by VW and AM. VW, AM and
412 TM conducted the data analysis. RM, VW, and SG wrote the first draft of the manuscript. SK,
413 ADM, PA, PB, CL, XD, DB, and SO contributed substantially to manuscript revisions. All authors
414 contributed to interpreting the results and reviewing different drafts of the manuscript. All
415 authors read and approved the final draft.

416 **Declarations**

417 [Data availability](#)

418 The data presented in this research are available upon a reasonable request to the
419 corresponding author.

420 [Competing Interests](#)

421 The authors declare no competing interests.

422 [Ethical review and approval](#)

423 This study is covered under the protocol approved by the Eswatini Health and Human
424 Research Review Board (EHRRB 116/2022) for Georgetown University to analyse program
425 data for dissemination. The EHRRB also approved a waiver of informed consent by patients.
426 Additional approval has been obtained from the Georgetown University Institutional Review
427 Board (GU - IRB) (STUDY 00006034) and the United States Centers for Disease Control (CDC)
428 (Accession #: CGH-ESW-9/14/23-15af6). Anonymised data were used to ensure
429 confidentiality and the EHRRB also approved an application for a waiver of written informed
430 consent from participants since the data is from routine care extracted from the electronic
431 medical records.

432

433

434

435 REFERENCES

- 436 1. World Health Organisation. WHO Cervical Cancer Elimination Initiative: from call to
437 action to global movement [Internet]. Geneva: WHO; 2023 May [cited 2023 1 Nov].
438 Available from: [https://www.who.int/publications/m/item/who-cervical-cancer-](https://www.who.int/publications/m/item/who-cervical-cancer-elimination-initiative--from-call-to-action-to-global-movement)
439 [elimination-initiative--from-call-to-action-to-global-movement](https://www.who.int/publications/m/item/who-cervical-cancer-elimination-initiative--from-call-to-action-to-global-movement)
- 440 2. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global
441 estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the
442 WHO Global Cervical Cancer Elimination Initiative. *Lancet Glob Health*. 2023
443 Feb;11(2):e197–206.
- 444 3. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and
445 immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like
446 particle vaccine. *J Natl Cancer Inst*. 2001 Feb 21;93(4):284–92.
- 447 4. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of
448 the global burden of cervical cancer associated with HIV. *Lancet Glob Health*. 2021
449 Feb;9(2):e161–9.
- 450 5. Massad LS, Hessol NA, Darragh TM, Minkoff H, Colie C, Wright RL, et al. Cervical cancer
451 incidence after up to 20 years of observation among women with HIV. *Int J Cancer*. 2017
452 15 Oct;141(8):1561–5.
- 453 6. World Health Organisation. Consolidated guidelines on the use of anti-retroviral drugs
454 for treating and preventing HIV infection: recommendations for a public health
455 approach, 2nd ed [Internet]. Geneva: WHO; 2016 Jun [cited 2023 1 Nov]. Available from:
456 <https://www.who.int/publications-detail-redirect/9789241549684>
- 457 7. Castle PE, Einstein MH, Sahasrabudhe VV. Cervical cancer prevention and control in
458 women living with human immunodeficiency virus. *CA Cancer J Clin*. 2021
459 Nov;71(6):505–26.
- 460 8. World Health Organisation. Global strategy to accelerate the elimination of cervical
461 cancer as a public health problem [Internet]. Geneva: WHO; 2020 Nov [cited 2023 1
462 Nov]. Available from: [https://www.who.int/publications-detail-](https://www.who.int/publications-detail-redirect/9789240014107)
463 [redirect/9789240014107](https://www.who.int/publications-detail-redirect/9789240014107)
- 464 9. Denny L. Cytological screening for cervical cancer prevention. *Best Pract Res Clin Obstet*
465 *Gynaecol*. 2012 Apr;26(2):189–96.
- 466 10. Sami J, Lemoupa Makajio S, Jeannot E, Kenfack B, Viñals R, Vassilakos P, et al.
467 Smartphone-Based Visual Inspection with Acetic Acid: An Innovative Tool to Improve
468 Cervical Cancer Screening in Low-Resource Setting. *Healthc Basel Switz*. 2022 Feb
469 18;10(2):391.
- 470 11. Cubie HA, Campbell C. Cervical cancer screening - The challenges of complete pathways
471 of care in low-income countries: Focus on Malawi. *Womens Health Lond Engl*.
472 2020;16:1745506520914804.
- 473 12. World Health Organisation. WHO guideline for screening and treatment of cervical pre-
474 cancer lesions for cervical cancer prevention, second edition [Internet]. Geneva: WHO;
475 2021 Dec [cited 2023 1 Nov]. Available from: [https://www.who.int/publications-detail-](https://www.who.int/publications-detail-redirect/9789240040434)
476 [redirect/9789240040434](https://www.who.int/publications-detail-redirect/9789240040434)

- 477 13. UNAIDS. UNAIDS Country Factsheet: Eswatini 2022 [Internet]. 2023 [cited 2023 1 Nov].
478 Available from: <https://www.unaids.org/en/regionscountries/countries/swaziland>
- 479 14. Eswatini Ministry of Health. National Cancer Control Program: Cervical Cancer Screening
480 Report 2019. Mbabane, Eswatini: MOH; 2020.
- 481 15. Eswatini Ministry of Health. Support Eswatini Achieve Sustained HIV Epidemic Control
482 (SEASEC): Data for accountability, transparency, and Impact (DATIM) April - June 2023
483 Report for Lubombo and Manzini Regions. Mbabane: MOH; 2023 Jul.
- 484 16. Jolly PE, Mthethwa-Hleta S, Padilla LA, Pettis J, Winston S, Akinyemiju TF, et al.
485 Screening, prevalence, and risk factors for cervical lesions among HIV positive and HIV
486 negative women in Swaziland. *BMC Public Health*. 2017 Feb 21;17(1):218.
- 487 17. Jolly PE, Mthethwa-Hleta S, Padilla LA, Pettis J, Winston S, Akinyemiju TF, et al.
488 Screening, prevalence, and risk factors for cervical lesions among HIV positive and HIV
489 negative women in Swaziland. *BMC Public Health*. 2017 Feb 21;17(1):218.
- 490 18. Pry JM, Manasyan A, Kapambwe S, Taghavi K, Duran-Frigola M, Mwanahamuntu M, et
491 al. Cervical cancer screening outcomes in Zambia, 2010-19: a cohort study. *Lancet Glob
492 Health*. 2021 Jun;9(6):e832-40.
- 493 19. Ogunsola OO, Ajayi OA, Ojo TO, Osayi E, Wudiri K, Amoo B, et al. Cervical cancer
494 screening and treatment for PLWHIV: experiences from an innovative program in
495 Nigeria. *Reprod Health*. 2023 Aug 26;20(1):125.
- 496 20. Segondy M, Kelly H, Magooa MP, Djigma F, Ngou J, Gilham C, et al. Performance of
497 careHPV for detecting high-grade cervical intraepithelial neoplasia among women living
498 with HIV-1 in Burkina Faso and South Africa: HARP study. *Br J Cancer*. 2016 9
499 Aug;115(4):425-30.
- 500 21. Kiros M, Mesfin Belay D, Getu S, Hailemichael W, Esmael A, Anduaalem H, et al.
501 Prevalence and Determinants of Pre-Cancerous Cervical Lesion and Human
502 Papillomavirus Among HIV-Infected and HIV-Uninfected Women in North-West
503 Ethiopia: A Comparative Retrospective Cross-Sectional Study. *HIV/AIDS Auckl NZ*.
504 2021;13:719-25.
- 505 22. Ibrahim Khalil A, Mpunga T, Wei F, Baussano I, de Martel C, Bray F, et al. Age-specific
506 burden of cervical cancer associated with HIV: A global analysis with a focus on sub-
507 Saharan Africa. *Int J Cancer*. 2022 1 Mar;150(5):761-72.
- 508 23. Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P, ART and HPV Review Group.
509 Association of anti-retroviral therapy with high-risk human papillomavirus, cervical
510 intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a
511 systematic review and meta-analysis. *Lancet HIV*. 2018 Jan;5(1):e45-58.
- 512 24. Daniel GO, Musa J, Akindigh TM, Shinku F, Shuaibu SI, Kwaghe B, et al. Prevalence and
513 predictors of pre-cancerous cervical lesions among HIV-positive women in Jos, north-
514 central Nigeria. *Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet*. 2020
515 Nov;151(2):253-9.
- 516 25. Kafuruki L, Rambau PF, Massinde A, Masalu N. Prevalence and predictors of Cervical
517 Intraepithelial Neoplasia among HIV infected women at Bugando Medical Centre,
518 Mwanza-Tanzania. *Infect Agent Cancer*. 2013 Nov 15;8(1):45.

519 26. Fentie AM, Tadesse TB, Gebretekle GB. Factors affecting cervical cancer screening
520 uptake, visual inspection with acetic acid positivity and its predictors among women
521 attending cervical cancer screening service in Addis Ababa, Ethiopia. BMC Womens
522 Health. 2020 Jul 16;20(1):147.

523

524

525

526

527




Figure 1_Distribution of health facilities